Vaccine Overview for
Primary Series Vaccination
Looking for information on adult primary series vaccination?Visit HCP site for spikevax
(COVID‑19 vaccine, mRNA)
5.5 mL vial for primary series doses or booster doses
2.5 mL vial for booster dose only
Dosing & Administration
The Moderna COVID‑19 Vaccine is administered as a primary series by intramuscular injection of two doses (0.5 mL each) 1 month apart to individuals 18 years of age or older.
A third primary series dose of the Moderna COVID‑19 Vaccine (0.5 mL) at least 1 month following the second dose is authorized for administration to individuals at least 18 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
The booster dose of Moderna COVID-19 Vaccine may be administered from two different vial presentations. When using the 5.5 mL multiple-dose vial with a red cap and a label with a light blue border, the dose is 0.25 mL. When using the booster-only multiple-dose vial with a dark blue cap and a label with a purple border, the booster dose is 0.5 mL.
A first Moderna COVID‑19 Vaccine booster dose may be administered intramuscularly at least 5 months after completing a primary series of the Moderna COVID‑19 Vaccine or spikevax (COVID-19 Vaccine, mRNA) to individuals 18 years of age or older.
A first booster dose of the Moderna COVID‑19 Vaccine may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID‑19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
A second booster dose of the Moderna COVID‑19 Vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID‑19 vaccine.
A second booster dose of the Moderna COVID‑19 Vaccine may be administered at least 4 months after receipt of a first booster dose of any authorized or approved COVID‑19 vaccine to individuals 18 years of age and older with certain kinds of immunocompromise.Get full dosing details
Clinical Trial Data
The Moderna COVID‑19 Vaccine is being evaluated in an ongoing Phase 3 randomized, placebo‑controlled, observer‑blind clinical trial conducted in the United States.See clinical trial data